Details for Patent: 6,536,427

Title:	Inhalation device
Abstract:	An inhalation device is described for use with a medicament pack in which at least one container for medicament in powder form is defined between two sheets peelably secured to one another. The device comprises means for peeling the sheets apart at an opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale medicament in powder form from the opened container.
Inventor(s):	Davies; Michael Birsha (Ware, GB), Hearne; David John (Luton, GB), Rand; Paul Kenneth (Letchworth, GB), Walker; Richard Ian (Ware, GB), Palmer; James Barry Douglas (Greenford, GB)
Assignee:	Glaxo Group Limited (Middlesex, GB)
Filing Date:	Aug 09, 2001
Application Number:	09/925,614
Claims:	1. A medicament pack for use in an inhalation device, the pack comprising an elongate strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet hermetically but peelably sealed thereto to define a plurality of containers, each container having therein inhalable medicament in powder form, the medicament comprising an active ingredient selected from the group consisting of albuterol, salmeterol, formoterol, fluticasone, beclomethasone, ciclesonide, mometasone, physiologically acceptable salts, esters and solvates of all the aforesaid, and budesonide and solvates thereof. 2. A medicament pack as claimed in claim 1, wherein the strip is sufficiently flexible to be wound into a roll. 3. A medicament pack as claimed in claim 1, wherein the lid sheet and base sheet have leading end portions which are not sealed to one another. 4. A medicament pack as claimed in claim 3, wherein at least one of the said leading end portions is constructed to be attached to a winding means. 5. A medicament pack as claimed in claim 1, wherein the hermetic seal between the base and the lid sheets extends over their whole width. 6. A medicament pack according to claim 1, wherein the lid sheet may be peeled from the base sheet in a longitudinal direction from a first end of the said base sheet. 7. A medicament pack as claimed in claim 1, wherein said active ingredient is fluticasone propionate. 8. A medicament pack as claimed in claim 1, wherein the said active ingredient is salmeterol xinafoate. 9. A medicament pack as claimed in claim 1, wherein the medicament pack comprises an active ingredient selected from the group consisting of salbutamol, salmeterol, formoterol, and physiologically acceptable salts, esters or solvates of all the aforesaid, in combination with an active ingredient selected from the group consisting of beclomethasone, mometasone, ciclesonide, fluticasone, physiologically acceptable salts, esters or solvates of any of the aforesaid, and budesonide. 10. A medicament pack as claimed in claim 9, wherein the medicament comprises fluticasone propionate in combination with an active ingredient selected from the group consisting of salmeterol and physiologically acceptable salts of salmeterol. 11. A medicament pack as claimed in claim 10, wherein the medicament comprises fluticasone propionate and salmeterol xinofoate. 12. A medicament pack as claimed in claim 9, wherein the medicament comprises budesonide in combination with an active ingredient selected from the group consisting of formoterol and physiologically acceptable salts of formoterol. 13. A medicament pack as claimed in claim 12, wherein the medicament comprises budesonide and formoterol fumarate. 14. In combination, an inhalation device and a medicament pack received therein, said medicament pack comprising an elongated strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet peelably sealed in superposed relationship thereto to define a plurality of containers, each having inhalable medicament in powder form, the medicament comprising an active ingredient selected from the group consisting of albuterol, salmeterol, formoterol, fluticasone, beclomethasone, ciclesonide, mometasone physiologically accepted salts, esters and solvates of all the aforesaid, budesonide and solvates thereof; and said inhalation device comprising: an opening station receiving a container of said medicament pack; a peeler positioned to engage peelable sheets of a container which has been received in said opening station so as to peel apart the peelable sheets, opening the container; and an outlet positioned in communication with an opened container through which a user inhale the medicament in powder form from the opened container. 15. The combination of claim 14, wherein said active ingredient is fluticasone propionate. 16. The combination of claim 14, wherein said active ingredient is salmeterol xinafoate. 17. The combination of claim 14, wherein the medicament comprises an active ingredient selected from the group consisting of salbutamol, salmeterol, formoterol, and physiologically acceptable salts, esters or solvates of all the aforesaid, in combination with an active ingredient selected from the group consisting of beclomethasone, fluticasone, ciclesonide, mometasone, physiologically acceptable salts, esters or solvates of any of the aforesaid, and budesonide. 18. The combination of claim 17, wherein the medicament comprises fluticasone propionate in combination with an active ingredient selected from the group consisting of salmeterol and physiologically acceptable salts of salmeterol. 19. The combination of claim 18, wherein the medicament comprises fluticasone propionate and salmeterol xinofoate. 20. The combination of claim 17, wherein the medicament comprises budesonide in combination with an active ingredient selected from the group consisting of formoterol and physiologically acceptable salts of formoterol. 21. The combination of claim 20, wherein the medicament comprises budesonide and formoterol fumarate. 22. The combination of claim 18, wherein the medicament comprises budesonide in combination with an active ingredient selected from the group consisting of formoterol and physiologically acceptable salts of formoterol. 23. The combination of claim 22, wherein the medicament comprises budesonide and formoterol fumarate.